Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed…

By P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, Marco Caputo, E. Zanolin, M. Muggeo. Journal of Clinical Endocrinology and Metabolism, 2000

789 citations recorded by the source corpus.

Subfields: Public Health, Environmental and Occupational Health, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/c72c2aa6e835d4a9f907cf5d2d2cb58ad736cd30

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Public Health, Environmental and Occupational Health

1. R. Norman
2. E. Diamanti-Kandarakis
3. Bart C. J. M. Fauser

In Reproductive Medicine

1. H. Escobar-Morreale
2. R. Norman
3. E. Diamanti-Kandarakis
4. Bart C. J. M. Fauser
5. D. Dumesic
6. Massimo F. Piepoli

Citations in the corpus

• Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. (2010, background): “A 2-h post 75-g oral glucose challenge be performed in PCOS women with a BMI greater than 30 kg/m2, or alternatively in lean PCOS women with advanced age ( 40 yr), personal history of gestational diabetes, or family history of T2DM (44, 93).”
• Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. (2000, background): “On the other hand, with the exception of one study (20), the administration of insulinlowering drugs, such as diazoxide (21), metformin (6, 22, 23), troglitazone (24), and (more recently) D-chito-inositol (25), has been proved to obtain the same results, regardless of significant changes in body wei”
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). (2004, background): “Currently there are scant data to indicate that markers of insulin resistance predict responses to treatment (Moghetti et al., 2000; Imani et al., 2000; Azziz et al., 2001).”
• Metformin: An Update (2002, background): “Hyperinsulinemia reflecting insulin resistance is a common feature in lean and obese patients with the polycystic ovary syndrome (11, 56, 57).”